Science Advances:智能隐形眼镜可监测并治疗糖尿病

2020-04-29 竹子 转化医学网

导言:除了矫正视力以外,隐形眼镜还有个令人意外的功能——监测并治疗糖尿病。这听起来像是在拍科幻大片,但没有科学家做不到的,只有人们想不到的。这在医疗界引起了极大的关注

导言:除了矫正视力以外,隐形眼镜还有个令人意外的功能——监测并治疗糖尿病。这听起来像是在拍科幻大片,但没有科学家做不到的,只有人们想不到的。这在医疗界引起了极大的关注,医学专家认为,这款隐形眼镜不仅给糖尿病患者带来了福音,还可以对它进行改造,将其改造成通过检测眼泪中的其他相关物质来监测其他疾病的另一工具。

糖尿病患者需要通过在饭前和饭后抽血来测量血糖水平,并且容易因糖尿病而引起并发症。韩国浦项科技大学(POSTECH)的一个研究小组,之前开发出了一项技术,只需戴上“智能发光二极管(LED)隐形眼镜”就可以诊断糖尿病和治疗糖尿病性视网膜病。通过这种技术,可穿戴式糖尿病诊断和治疗设备的开发将受到鼓舞。此前,有研发者认为LED等中的砷会对眼睛造成伤害故而放弃了,好在科学家仍不放弃,完成了这一创举。

近日,该研究小组对动物的新的初步研究表明,隐形眼镜还可以监测人的糖尿病并提供药物。研究结果发表在4月24日的《科学进展》 杂志上。

新镜片旨在监测血糖水平并向眼睛输送药物,可能用于与糖尿病相关的眼病,称为糖尿病性视网膜病。在将它们试戴在兔子上后,科学家发现新镜片在两种情况下都有效。

研究人员指出,已经有一种经美国食品和药物管理局(FDA)批准的隐形眼镜,该隐形眼镜可以在一夜之间测量眼睛的压力。眼压水平对于患有眼部疾病的青光眼患者来说非常重要。

资深研究作者,韩国浦项科技大学教授,加州斯坦福大学的客座教授Sei Kwang Hahn表示,在各种可穿戴设备中,智能隐形眼镜在医疗保健领域特别有前景,因为它可以用作人体和电子设备之间的接口。

这是第一项隐形眼镜结合血糖感应和药物输送技术的研究。但是,在动物中行之有效的方法在人类中并不总是行之有效的。

智能隐形眼镜包含超薄而灵活的电路和微控制器芯片。目前的厚度约为0.2毫米,研究人员希望将厚度减小到0.15毫米。目前的镜片已经比FDA批准的可测量眼压的镜片更薄。

美国眼科学院的临床发言人约翰·霍瓦尼斯安(John Hovanesian)博士说,这种镜片戴着足够舒服,但比标准的隐形眼镜要厚得多。

隐形眼镜上的化学物质与葡萄糖结合,并触发与葡萄糖量成比例的电流变化。电流会用来溶解金膜,这些金膜密封了药物储存器,从而触发了一定剂量的药物释放。

隐形眼镜监测眼睛中葡萄糖的最大挑战之一是,必须谨慎使用糖尿病患者的隐形眼镜,因为感染和伤害可能会更加严重。


模具上的智能隐形眼镜,可用于糖尿病诊断和糖尿病性视网膜病的治疗。

与此同时,还有许多令人兴奋的可能性。一种大的可能性是有可能通过提供通常隐形眼镜用于治疗糖尿病性视网膜病的药物。这些药物目前是通过注射输送到眼睛的。

在这项研究中,研究人员使用了一种名为“染料木黄酮”的药物,该药物未经美国FDA批准。

JDRF(以前为青少年糖尿病研究基金会)的研究副总裁桑杰·杜特(Sanjoy Dutta)说,他们已经完成了良好的临床前准备工作。展望未来,他们需要知道泪糖与血糖相比有多准确。致命弱点可能在于连接两个组件(葡萄糖感测和药物输送)。

杜特说,有许多研究项目正在寻找无需抽血或不佩戴连续血糖监测仪即可测量血糖水平的方法。已经尝试或正在尝试的其他一些选择是通过汗水、眼泪、唾液和红外线进行监测。


用于糖尿病监测和糖尿病性视网膜病治疗的智能隐形眼镜。

任何非基于血液的葡萄糖监测都是非常具有挑战性的。研究人员希望在2021年开始进行人体临床试验。如果进展顺利,在2023年之前会推出相关产品。

原始出处:

Do Hee Keum, Su-Kyoung Kim1, Jahyun Koo, et.al. Wireless smart contact lens for diabetic diagnosis and therapy. Science Advances 24 Apr 2020: Vol. 6, no. 17, eaba3252

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1376081, encodeId=797b13e6081c7, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560420, encodeId=97d5156042065, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566429, encodeId=e5da156642990, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589442, encodeId=4bd115894429d, content=<a href='/topic/show?id=fb149850ed9' target=_blank style='color:#2F92EE;'>#隐形眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98507, encryptionId=fb149850ed9, topicName=隐形眼镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043098, encodeId=5202104309877, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 29 12:46:46 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-05-01 jichang
  2. [GetPortalCommentsPageByObjectIdResponse(id=1376081, encodeId=797b13e6081c7, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560420, encodeId=97d5156042065, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566429, encodeId=e5da156642990, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589442, encodeId=4bd115894429d, content=<a href='/topic/show?id=fb149850ed9' target=_blank style='color:#2F92EE;'>#隐形眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98507, encryptionId=fb149850ed9, topicName=隐形眼镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043098, encodeId=5202104309877, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 29 12:46:46 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1376081, encodeId=797b13e6081c7, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560420, encodeId=97d5156042065, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566429, encodeId=e5da156642990, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589442, encodeId=4bd115894429d, content=<a href='/topic/show?id=fb149850ed9' target=_blank style='color:#2F92EE;'>#隐形眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98507, encryptionId=fb149850ed9, topicName=隐形眼镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043098, encodeId=5202104309877, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 29 12:46:46 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1376081, encodeId=797b13e6081c7, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560420, encodeId=97d5156042065, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566429, encodeId=e5da156642990, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589442, encodeId=4bd115894429d, content=<a href='/topic/show?id=fb149850ed9' target=_blank style='color:#2F92EE;'>#隐形眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98507, encryptionId=fb149850ed9, topicName=隐形眼镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043098, encodeId=5202104309877, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 29 12:46:46 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1376081, encodeId=797b13e6081c7, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560420, encodeId=97d5156042065, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566429, encodeId=e5da156642990, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589442, encodeId=4bd115894429d, content=<a href='/topic/show?id=fb149850ed9' target=_blank style='color:#2F92EE;'>#隐形眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98507, encryptionId=fb149850ed9, topicName=隐形眼镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri May 01 00:46:46 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043098, encodeId=5202104309877, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 29 12:46:46 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-04-29 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Sci Transl Med:基因编辑患者的干细胞可逆转糖尿病

导言:研究人员使用从罕见Wolfram综合症患者的皮肤中产生的诱导性多能干细胞,将人类干细胞转化为产生胰岛素的细胞,并使用基因编辑工具CRISPR-Cas9进行校正导致该综合征的遗传缺陷。然后,他们将

Lancet Diabetes Endocrinol:2型糠尿病老年患者面临更高的COVID-19死亡风险

导言:《柳叶刀肿瘤》上前有研究表明,COVID-19患者中,同时患有癌症的人死亡风险更高。武汉大学中南医院的研究团队发现与年龄相关的基础疾病,如高血压和糖尿病等,会明显减缓COVID-19患者体内病毒

报告称:糖尿病患病率升高 降糖药市场多年保持增长

广州4月21日电 (蔡敏婕)医药健康领域的数据信息服务平台米内网21日发布消息称,内地公立医院渠道的降糖药市场连续多年来保持增长,目前已经突破510亿元。

Diabetologia: 肥胖加5倍糖尿病风险!丹麦研究

父母没有糖尿病,就能放纵体重?

J Rheumatol:急性胰腺炎后痛风与糖尿病的关系

胰腺炎后痛风与PPDM的关系是双向的。痛风病史是PPDM的危险因素,特别是在女性中。

剖宫产增加肥胖和糖尿病风险!JAMA子刊研究

近期,JAMA网络开放子刊上发表的一项来自美国的大规模前瞻性队列研究结果提示,与经阴道分娩的人相比,剖宫产儿成年后肥胖和出现2型糖尿病的风险均显著增加。

拓展阅读

BMC Public Health:苏丹北部成年人打鼾与高血压和糖尿病相关

苏丹北部大约四分之一的成年人打鼾。打鼾在肥胖的成年人中更为常见,同时打鼾与高血压和2型糖尿病的发病率增加有关。

MC Cardiovasc Disord:预测急性失代偿慢性心力衰竭和糖尿病患者在重症监护病房48小时后住院死亡率的新模型

本研究构建了一种简单而准确的诺模图来预测ADCHF合并糖尿病患者的住院死亡率,尤其是那些在重症监护病房住院超过48小时的患者,有助于临床医生评估风险并对患者进行个体化治疗,从而降低住院死亡率。

Environ Health Prev Med :母亲糖尿病和后代先天性心脏病风险的关系

先天性心脏病是新生儿中最常见的先天性疾病。然而,成年重度冠心病患者的生存率明显低于普通人群。

改善糖尿病合并CKD患者结局的综合管理策略(IWGDF 2023)

改善糖尿病合并CKD患者结局的综合管理策略(IWGDF 2023)

Front Cardiovasc Med:RF-CL与CACS-CL模型对稳定型心绞痛合并糖尿病患者冠状动脉阻塞预测概率和预测预后方面的比较

预计到2045年,全球糖尿病(DM)患者人数将增至7亿。全球葡萄糖代谢受损的负担日益加重。

Adv Sci:空军军医大学陈俊/武俊杰发现糖尿病前期神经病理性疼痛新型治疗靶点

该研究旨在探讨PDNP的发生机制并确定潜在的治疗靶点。